Evidence map›Paper›PMID 26992853›Full record

ArticleJournal of ovarian research2016

A centrosome clustering protein, KIFC1, predicts aggressive disease course in serous ovarian adenocarcinomas.

Karuna Mittal, Da Hoon Choi, Sergey Klimov, Shrikant Pawar, Ramneet Kaur, Anirban K Mitra, Meenakshi V Gupta, Ralph Sams, Guilherme Cantuaria, Padmashree C G Rida and 1 more

Open access · goldAbstract read
In one paragraph

Article in Journal of ovarian research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. High Expression of KIFC1 in Glioma Correlates with Poor Prognosis.Journal of Korean Neurosurgical Society · 2024
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Karuna MittalDepartment of Biology, Georgia State University, Atlanta, GA, 30303, USA.
Da Hoon ChoiDepartment of Biology, Georgia State University, Atlanta, GA, 30303, USA.
Sergey KlimovDepartment of Biology, Georgia State University, Atlanta, GA, 30303, USA.
Shrikant PawarDepartment of Biology, Georgia State University, Atlanta, GA, 30303, USA.
Ramneet KaurDepartment of Mathematics, Science and Bioinformatics, Mercer University, Atlanta, GA, USA.
Anirban K MitraDepartment of Medical and Molecular Genetics, Medical Sciences Program, Indiana University School of Medicine, Bloomington, IN, USA.
Meenakshi V GuptaDepartment of Pathology, West Georgia Hospital, Lagrange, GA, USA.
Ralph SamsDepartment of Pathology, Northside Hospital, Atlanta, GA, USA.
Guilherme CantuariaDepartment of Gynecologic Oncology, Northside Hospital Cancer Institute, Atlanta, GA, USA.
Padmashree C G RidaDepartment of Biology, Georgia State University, Atlanta, GA, 30303, USA. cgp_rida@yahoo.com.
Ritu AnejaDepartment of Biology, Georgia State University, Atlanta, GA, 30303, USA. raneja@gsu.edu.
Georgia State University · USNorthside Hospital · USIndiana University School of MedicineMercer University · USMolecular Theranostics (United States) · US

Funding

Evaluation of HSET as a Novel Theranostic Target for Breast Cancer TherapyR01CA169127 · NCI · GEORGIA STATE UNIVERSITY · PI ANEJA, RITU · 2012 to 2016
$1.7M
Evaluation of centrosome amplification as a risk-predictor for breast cancer aggrU01CA179671 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ANEJA, RITU · 2014 to 2018
$1.6M
NCI NIH HHS R01 CA169127NCI NIH HHS U01 CA179671
6 · The paper itself

Abstract

backgroundAmplified centrosomes are widely recognized as a hallmark of cancer. Although supernumerary centrosomes would be expected to compromise cell viability by yielding multipolar spindles that results in death-inducing aneuploidy, cancer cells suppress multipolarity by clustering their extra centrosomes. Thus, cancer cells, with the aid of clustering mechanisms, maintain pseudobipolar spindle phenotypes that are associated with low-grade aneuploidy, an edge to their survival. KIFC1, a nonessential minus end-directed motor of the kinesin-14 family, is a centrosome clustering molecule, essential for viability of extra centrosome-bearing cancer cells. Given that ovarian cancers robustly display amplified centrosomes, we examined the overexpression of KIFC1 in human ovarian tumors.

resultsWe found that in clinical epithelial ovarian cancer (EOC) samples, an expression level of KIFC1 was significantly higher when compared to normal tissues. KIFC1 expression also increased with tumor grade. Our In silico analyses showed that higher KIFC1 expression was associated with poor overall survival (OS) in serous ovarian adenocarcinoma (SOC) patients suggesting that an aggressive disease course in ovarian adenocarcinoma patients can be attributed to high KIFC1 levels. Also, gene expression levels of KIFC1 in high-grade serous ovarian carcinoma (HGSOC) highly correlated with expression of genes driving centrosome amplification (CA), as examined in publically-available databases. The pathway analysis results indicated that the genes overexpressed in KIFC1 high group were associated with processes like regulation of the cell cycle and cell proliferation. In addition, when we performed gene set enrichment analysis (GSEA) for identifying the gene ontologies associated to KIFC1 high group, we found that the first 100 genes enriched in KIFC1 high group were from centrosome components, mitotic cell cycle, and microtubule-based processes. Results from in vitro experiments on well-established in vitro models of HGSOC (OVSAHO, KURAMOCHI), OVCAR3 and SKOV3) revealed that they display robust centrosome amplification and expression levels of KIFC1 was directly associated (inversely correlated) to the status of multipolar mitosis. This association of KIFC1 and centrosome amplification with HGSOC might be able to explain the increased aggressiveness in this disease.

conclusionThese findings compellingly underscore that KIFC1 can be a biomarker that predicts an aggressive disease course in ovarian adenocarcinomas.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorCentrosomeCystadenocarcinoma, SerousDisease ProgressionFemaleGene ExpressionHumansKaplan-Meier EstimateKinesinsMiddle AgedOvarian NeoplasmsYoung AdultBiomarkers, TumorKIFC1 protein, humanKinesinsCentrosome amplificationCentrosome clusteringKIFC1Serous ovarian adenocarcinoma

Identifiers

PMID26992853
PMCPMC5477851
OpenAlexW2298040877

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.